Legend Biotech.
Biotech company
- Reports this week
- 0
- Active events
- 0
- Connections
- 30
What's happening
Earlier this month
One to three months ago
-
Legend Biotech and Johnson & Johnson announced their collaboration on CARVYKTI, while Legend Biotech also utilized LinkedIn for professional presence.Well supported6 reports
-
Analysts view Legend Biotech's current valuations as a buying opportunity.Speculative1 report1 development inside
-
Royal Bank of Canada cut its price target on Legend Biotech in a research report.Some support2 reports
-
Legend Biotech listed its shares on the Nasdaq stock exchange and expanded its global market presence into Ireland.Some support3 reports
Gone quiet
No new reports in 90+ days-
Legend Biotech and Janssen Biotech announced a partnership on January 22, 2026, to advance cell therapy treatments. The companies are headquartered in Somerset, New Jersey.Some support1 report
-
Carlos Santos was appointed CFO of Legend Biotech, with financial expertise provided by AstraZeneca, Novartis, and Intel.Well supported5 reports
-
Micron Technology, AAON, Legend Biotech, and Franco-Nevada saw stock movements on August 12, 2025, following earnings reports, including surges, plunges, and rises.Some support1 report
-
Legend Biotech reported record CARVYKTI sales driving revenue growth, coinciding with an FDA label update to reduce monitoring.Some support1 report
-
Legend Biotech reported a Q2 beat, indicating strong demand and successful manufacturing.Some support2 reports
No events began in the chosen period. Widen it, or reset.
What's reaching Legend Biotech
Events traced to Legend Biotech, step by step, newest first- JNJ's financial strength could stabilize Legend Biotech partnershipJNJ's strong financial position may reinforce commitment to Legend Biotech partnershipPossible
- JNJ's new partnership could bolster Legend Biotech's strategic standingJNJ's expanded commercial reach may strengthen strategic partnerships like Legend Biotech'sPossible
Around Legend Biotech this week
News at the entities that move Legend Biotech most-
Johnson & Johnson StructuralJohnson & Johnson gained approval for its Icotyde treatment in the China market.Moves Legend Biotech
-
Novartis StructuralBristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.Moves Legend Biotech
-
Morgan Stanley Mentioned togetherMorgan Stanley upped its price objective and gave a buy rating, while Jefferies reiterated an underperform rating for Palantir Technologies.Moves Legend Biotech
-
LinkedIn OperationalThe government ordered LinkedIn to turn over records belonging to journalists, involving the Justice Department and the US President.Moves Legend Biotech
-
Nasdaq StructuralAerSale stock traded on Nasdaq and announced an expected $35M sale of a Boeing 737.Moves Legend Biotech
-
CAR StructuralDucks Unlimited Canada and CAR are collaborating on a broader conservation effort in Canada using CAR's Grassland Protocol.Moves Legend Biotech
Connections
The 15 strongest of 30, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Johnson & Johnson Structural
Legend Biotech and Johnson & Johnson maintain a deep structural partnership, co-developing and supplying the CARVYKTI treatment, cemented by J&J's investment in Legend's portfolio.
-
Ying Huang Structural
Ying Huang served as the Chief Executive Officer and Board member of Legend Biotech.
-
CAR Structural
The company's existence is fundamentally tied to the single CAR-T franchise technology.
-
Janssen Biotech Operational
Legend Biotech and Janssen Biotech are partnering to advance cell therapy treatments.
-
Novartis Structural
Legend Biotech leverages expertise and talent pools from Novartis, indicating a functional dependency on Novartis's ecosystem.
-
Carlos Santos Structural
Carlos Santos serves as the Chief Financial Officer of Legend Biotech.
-
Nasdaq Structural
Legend Biotech is formally listed and trades on the Nasdaq stock exchange, establishing a market dependency.
-
LinkedIn Operational
Legend Biotech utilizes LinkedIn as a platform for maintaining its professional presence.
Show all 15 connections
-
BioTech Operational
Both companies are described as competing for investment within the healthcare sector.
-
New Jersey Shared context
Legend Biotech is headquartered in Somerset, New Jersey.
-
Janssen Operational
The relationship is defined by a collaboration agreement that drives higher sales for Legend Biotech.
-
Royal Bank of Canada Mentioned together
Legend Biotech is the subject of financial analysis and valuation reports from the investment banking sector represented by Royal Bank of Canada.
-
AbbVie Mentioned together
Both entities are cited as major players operating within the competitive pharmaceutical sector.
-
Morgan Stanley Mentioned together
Morgan Stanley provides investment coverage, including target price and rating changes, for Legend Biotech.
-
Ireland Shared context
Legend Biotech is expanding its market presence and launching products in Ireland.
History
Events by the month they beganOctober 2026
1 eventAugust 2026
3 events- Royal Bank of Canada cut its price target on Legend Biotech in a research report.
- Legend Biotech listed its shares on the Nasdaq stock exchange and expanded its global market presence into Ireland.
- Legend Biotech and Janssen Biotech announced a partnership on January 22, 2026, to advance cell therapy treatments. The companies are headquartered in Somerset, New Jersey.
June 2026
6 events- Legend Biotech and Johnson & Johnson announced their collaboration on CARVYKTI, while Legend Biotech also utilized LinkedIn for professional presence.
- Analysts view Legend Biotech's current valuations as a buying opportunity.
- Carlos Santos was appointed CFO of Legend Biotech, with financial expertise provided by AstraZeneca, Novartis, and Intel.
- Micron Technology, AAON, Legend Biotech, and Franco-Nevada saw stock movements on August 12, 2025, following earnings reports, including surges, plunges, and rises.
- Legend Biotech reported record CARVYKTI sales driving revenue growth, coinciding with an FDA label update to reduce monitoring.
- Legend Biotech reported a Q2 beat, indicating strong demand and successful manufacturing.